Filter by
 

Publication date

Series/ Type

Series/type

Language

Main subject

Main subject

Keywords

Keywords

Publications database

Displaying 1 - 20 of 21

Rapid communication

Recreational use of nitrous oxide — a growing concern for Europe

November 2022

The purpose of this report is to examine the current situation, risks and responses to the recreational use of nitrous oxide in Europe. To support this, the report also provides a state-of-the-art review of the chemistry, pharmacology and toxicology of the gas. It is intended for policymakers and...

Rapid communication

New psychoactive substances: 25 years of early warning and response in Europe — an update from the EU Early Warning System

June 2022

This update from the EU Early Warning System overviews the NPS situation in Europe in 2020-2021 and highlights emerging threats to support early warning, preparedness planning and response measures. In addition, it reflects on the changes and the lessons learned from 25 years of monitoring NPS in...

Rapid communication

Synthetic cannabinoids in Europe – a review

September 2021

This report provides a technical review of the current body of knowledge regarding synthetic cannabinoids that are monitored by the the EU Early Warning System. The aim of this report is to strengthen situational awareness of synthetic cannabinoids in Europe and to help stakeholders prepare for,...

Rapid communication

New benzodiazepines in Europe – a review

June 2021

This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in Europe, and to help stakeholders prepare for and...

Rapid communication

New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic — an update from the EU Early Warning System

December 2020

In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. The report covers the period until October 2020 and this year focuses on...

Rapid communication

Drug-related deaths and mortality in Europe: update from the EMCDDA expert network

July 2019

This publication provides an update on drug-related deaths in Europe, presenting and analysing the latest data and trends in drug-induced deaths and overall mortality among high-risk drug users in the European Union and beyond. It draws on contributions from specialists representing more than 40...

Rapid communication

Drug-related infectious diseases in Europe: update from the EMCDDA expert network

June 2019

This report presents an overview of infectious diseases among people who inject drugs in Europe, both in the community and in prison settings, covering disease surveillance, outbreak investigations, and prevention and control, for the period up to the end of February 2019. The report describes the...

Rapid communication

Drugs in syringes from six European cities: results from the ESCAPE project 2017

May 2019

This report presents the results of an innovative method for gathering information on the substances used by people who inject drugs. In this pilot study, chemical analysis of the contents of used syringes collected from exchange sites reveals the drugs and drug combinations injected in the six...

Rapid communication

Recent changes in Europe’s cocaine market: results from an EMCDDA trendspotter study

December 2018

Using trendspotter methodology, this report explores signs of increasing availability and consumption of cocaine in Europe, in an effort to increase our understanding of recent changes in the cocaine market. The study investigates the consequences of these developments on acute health harms linked...

Rapid communication

Medical use of cannabis and cannabinoids: questions and answers for policymaking

December 2018

What is the evidence base for the medical use of cannabis and cannabinoids? What is the difference between cannabis preparations and medicinal products and why is this important? How is this issue regulated in the EU? These and other questions are explored in this report which responds to growing...

Rapid communication

Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation — an update from the EU Early Warning System

June 2018

In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. This report covers the period from January 2016 until December 2017.

Rapid communication

New psychoactive substances in prison

June 2018

This report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large share of drug-related problems in some European prisons...

Rapid communication

Drug-related infectious diseases in Europe: update from the EMCDDA expert network

November 2017

This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting,...

Rapid communication

High-risk drug use and new psychoactive substances – results from an EMCDDA trendspotter study

June 2017

This report provides a first look at the emergence of more problematic forms of use of new psychoactive substances among a range of demographic groups, including opioid and amphetamine injectors, prisoners, the homeless and men who have sex with men. It explores, in particular, the use of synthetic...

Rapid communication

Drug-related infectious diseases in Europe: update from the EMCDDA expert network

November 2016

This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting,...

Rapid communication

Hospital emergency presentations and acute drug toxicity in Europe — update from the Euro-DEN Plus research group and the EMCDDA

August 2016

This rapid communication provides an update on drug related hospital emergency presentations in Europe with a specific focus on the latest results for acute drug toxicity presentations to the European Drug Emergencies Network (Euro-DEN). This report is primarily based on presentations and...

Rapid communication

Health responses to new psychoactive substances

June 2016

While prevalence levels of NPS use remain low in the general European population, there are important concerns with more problematic forms of use and harms. This short report provides an overview of the current situation in terms of NPS use and harms across Europe and reviews the available health-...

Rapid communication

Recent changes in Europe’s MDMA/ecstasy market – results from an EMCDDA trendspotter study

May 2016

This report explores the recent resurgence in use of MDMA in Europe and increased availability of high-strength MDMA tablets, crystals and powders. It notes that the picture is not uniform across European countries, and while overall the region’s MDMA market is now in a period of consolidation,...

Rapid communication

Drug-related infectious diseases in Europe. Update from the EMCDDA expert network

September 2015

This report provides an update on infectious diseases related to injecting drug use in Europe for the period up to June 2015. The report covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. It includes highlights and...

Rapid communication

New psychoactive substances in Europe: Innovative legal responses

June 2015

This short report provides an overview of how European countries are developing innovative legal responses to the challenges presented to public health and drug policy by the rapidly evolving market for new psychoactive substances.

Loading